NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 77

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302214

Licensee	
1. Froedtert Memorial Lutheran Hospital 2. 9200 W. Wisconsin Avenue Milwaukee, WI 53226	In accordance with letter dated January 10, 1997 3. License Number 48-04193-01 is amended in its entirety to read as follows:
	4. Expiration Date April 30, 2003
	5. Docket or Reference No. 030-03444

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500	E. As needed
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed
G. Any byproduct material with Atomic Nos. 3-83; inclusive, with half-lives less than or equal to 120 days	G. Any	G. Not to exceed 100 millicuries per radionuclide. Total possession not to exceed 30 curies except as listed below:

260015

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-04193-01

Docket or Reference Number
030-03444

Amendment No. 77

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
H. Phosphorus-32	H. Any	H. 1000 millicuries
I. Phosphorus-33	I. Any	I. 500 millicuries
J. Sulfur-35	J. Any	J. 1000 millicuries
K. Chromium-51	K. Any	K. 500 millicuries
L. Iodine-125	L. Any	L. 750 millicuries
M. Iodine-131	M. Any	M. 500 millicuries
N. Any byproduct material with Atomic Nos. 1-83; inclusive, with half-lives greater than 120 days	N. Any	N. Possession limit not to exceed 10^4x 10 CFR Part 30 Appendix B limits for each radionuclide. Total possession not to exceed R/10^4 is less than or equal to 1; R is the sum of the ratios of the quantity of each radionuclide to the applicable value in 10 CFR Part 30 Appendix B.
O. Any byproduct material with Atomic Nos. 3-83; inclusive	O. Sealed sources (registered pursuant to Section 32.2110 of 10 CFR Part 32 or an Agreement State)	O. 2 curies
P. Iridium-192	P. Sealed sources (BYK Mallinckrodt Model CIL BV)	P. Two sources not to exceed 12 curies each

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-04193-01

Docket or Reference Number
030-03444

Amendment No. 77

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
Q. Iridium-192	Q. Brachytherapy source wire (CIS-US, Inc. Model IRF, IREC or IREL Series)	Q. Not to exceed 150 millicuries per source. Total activity not to exceed 2500 millicuries.
R. Americium-241	R. Sealed sources (registered pursuant to Section 32.210 of 10 CFR Part 32 or an Agreement State)	R. 100 millicuries

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. Medical use described in 10 CFR 35.400 and for interstitial; intracavitary; intraluminal; or plesiotherapy treatment including the use of iodine-125 as sealed sources in seeds in an eye plaque.

E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

F. In vitro studies.

G. through O. To be used for research and development as described in letter (with attachments) dated January 20, 1993, excluding human research outside the confines of an FDA approved IND, NDA or RDRC.

P. One source to be used in a Nucletron Corporation MicroSelectron HDR remote afterloading brachytherapy device for interstitial and intracavitary radiotherapy in humans, in accordance with Condition 34. of this license. One source in its shipping container to be in possession of the licensee as necessary for replacement of the source in the irradiation device.

Q. To be used for interstitial, intercavitary, intraluminal and plesiotherapy treatment of cancer.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-04193-01

Docket or Reference Number
030-03444

Amendment No. 77

R. To be used for research and development as described in letter (with attachments) dated January 20, 1993 excluding human research outside the confines of an FDA approved IND, NDA or RDRC.

CONDITIONS

10. A. Licensed material shall be used only at the licensee's facilities located at 8700 W. Wisconsin Avenue and 8701 Watertown Plank Road, Milwaukee, Wisconsin. Licensed material for medical diagnosis and therapy may also be used at Foedtert Memorial Hospital, 9200 West Wisconsin Avenue, Milwaukee, Wisconsin.

B. Licensed material listed in Item 6.P. shall be used only at the licensee's facilities located in rooms 37-1 or 37-5, Radiation Oncology Department, Basement, N-S Wing, 8700 West Wisconsin Avenue, Milwaukee, Wisconsin.

11. The Radiation Safety Officer for this license is Ralph Grunewald, Ph.D.

12. A. The use of licensed material in or on humans shall be by a physician, dentist, or podiatrist as defined in 10 CFR 35.2.

B. Physicians, dentists, or podiatrists designated to use licensed material in or on humans shall meet the training criteria established in 10 CFR 35, Subpart J(a) and shall be designated by the licensee's Radiation Safety Committee. The licensee shall maintain records of individuals designated as users for three years after the individual's last use of licensed material.

C. Licensed material for other than human use shall be used by or under the supervision of individuals designated by the Radiation Safety Committee. The licensee shall maintain records of individuals designated as users for three years after the individual's last use of licensed material.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.

14. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

E. Sealed sources need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region III, 801 Warrenville Road, Lisle, Illinois 60532-4351, ATTN: Chief, Nuclear Materials Safety Branch. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

G. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to Perform such services.

15. Pursuant to 10 CFR Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material.

16. The licensee shall conduct a physical inventory every 3-months to account for all sources and/or devices received and possessed pursuant to 10 CFR 35.59, 10 CFR 35.400 and 10 CFR 35.500 and every 6 months for all other sources and/or devices. Records of inventories shall be maintained for 5 years from the date of each inventory, and shall include the information required in 10 CFR 35.59(g).

17. A. Detector cells containing a titanium tritide foil or a scandium tritide foil shall only be used in conjunction with a properly operating temperature control mechanism which prevents the foil temperature from exceeding that specified by the manufacturer and approved by U.S. Nuclear Regulatory Commission.

    B. When in use, detector cells containing a titanium tritide foil or a scandium tritide foil shall be vented to the outside.

18. In lieu of using the conventional radiation caution colors (magenta or purple on yellow background) as provided in 10 CFR 20.203(a)(1), the licensee is hereby authorized to label detector cells, containing licensed material and used in gas chromatography devices, with conspicuously etched or stamped radiation caution symbols.

19. Notwithstanding the requirements of 10 CFR 35.49(a) and (b), 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, 10 CFR 35.400, and 10 CFR 35.500, the licensee may use for any medical use any byproduct material or reagent kit. The licensee shall possess and use byproduct material for medical use in accordance with the prescriptive and performance criteria in the other sections of 10 CFR 35. This does not relieve the licensee from complying with applicable United States Food and Drug Administration (FDA) and other Federal and State requirements.

20. The licensee shall possess and use byproduct material for human research use in accordance with the prescriptive and performance criteria in all sections of 10 CFR Part 35 except Sections 35.49(a) and (b), 35.100, 35.200, and 35.300.

21. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

22. The licensee is authorized to hold radioactive material with a physical half-life of less than 120 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

    B. Before disposal as ordinary trash, byproduct material shall be surveyed at the container surface with the appropriate meter set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

D. A record of each disposal permitted under this License Condition shall be retained for 3 years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

23. Experimental animals, or the products from experimental animals, that have been administered licensed materials shall not be used for human consumption.

24. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

25. The licensee shall maintain records of information related to decommissioning at 9200 W. Wisconsin Avenue, as specified in 10 CFR 30.35(g) until this license is terminated by the Commission.

26. A. Access to the rooms housing the MicroSelectron-HDR afterloading brachytherapy unit shall be controlled by a door at each entrance.

B. The entrance to the irradiation room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on the entrance door to the irradiator room shall be tested for proper operation at least once a month. Records of test results shall be maintained for inspection by the Commission.

D. In the event of malfunction of the door interlock, the irradiation device shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

27. Prior to initiation of a treatment program, and subsequent to each source exchange for the MicroSelectron-HDR afterloading brachytherapy units, radiation surveys and tests shall be performed in accordance with the following:

A. A radiation survey shall be made of:

(1) The irradiator source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 milliroentgen per hour.

(2) All areas adjacent to the treatment room with the source in the "irradiation" position. The survey shall clearly establish:

(a) That radiation levels in restricted areas are not likely to cause personnel exposure in excess of the limits specified in 10 CFR 20.1201.

(b) That quantities of radiation in unrestricted areas do not exceed the limits specified in 10 CFR 20.1301.

B. Records of the survey results shall be maintained for inspection by the Commission for the duration of the license.

28. The following shall be performed only by persons specifically authorized by the Commission or an Agreement State to perform such services:

A. Installation and replacement of the sealed sources contained in the MicroSelectron-HDR afterloading brachytherapy unit(s).

B. Any maintenance or repair operations on the MicroSelectron-HDR afterloading brachytherapy unit(s) listed in Item 9., Subitem(s) R. involving work on the source safe, the source driving unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

29. In addition to the possession limits in Condition 8, the licensee shall further restrict the possession of unsealed licensed material or readily dispersible source material to quantities less than 10^4 times the applicable limits in Appendix B of Part 30 as specified in 10 CFR 30.35(d).

30. Notwithstanding the provisions of 10 CFR 35.400(d), the licensee may use iridium-192 seeds encased in nylon ribbon as described in letter dated February 19, 1991, for intracavitary treatment of cancer.

31. Notwithstanding the provisions of 10 CFR 35.400(f), the licensee may use iodine-125 as sealed sources in seeds in an eye plaque as described in letters dated February 19, 1991 and June 6, 1991, for topical treatment of choroidal melanoma.

32. Notwithstanding the provisions of 10 CFR 35.59(a), the licensee may deviate from the radiation safety and handling instructions supplied by the manufacturer only for the iodine-125 eye plaque procedure as described in letters dated February 19, 1991 and June 6, 1991.

33. The licensee shall implement the procedures in 10 CFR 35.59 for iridium-192 wire identified in Subitem Q of Items 6., 7. and 8.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
48-04193-01

Docket or Reference Number
030-03444

Amendment No. 77

34. The licensee may possess 24 curies of iridium-192 (not to exceed 12 curies per source) for use in the Nucletron Corporation MicroSelectron HDR remote afterloading brachytherapy device, provided the individual source activity does not exceed 10 curies at the time of installation, and the source is installed by an authorized individual.

35. Notwithstanding the requirements of 10 CFR 35.404(a), the licensee may release from confinement for medical care a patient (described in letter dated July 22, 1996) with a temporary eye plaque implant in place, provided that the survey requirements for permanent implant patients specified in 10 CFR 35.75(b) are met. Upon removal of the eye plaque, the licensee shall make a radiation survey of the patient with a radiation detection survey instrument to confirm that all sources have been removed. This survey must include disassembling the plaque to conduct a physical inventory of the seeds. The licensee shall retain a record of the patient survey in accordance with 10 CFR 35.404(b).

36. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated February 18, 1992 (only); and

    B. Letters with attachments dated February 19, 1991, June 6, 1991, May 14, 1992, January 20, 1993; March 17, 1993, April 6, 1993 (excluding all references to move HDR unit between 2 treatment rooms), May 12, 1994, September 30, 1994, and August 11, 1995 (except Amendment Items 4. and 6.), December 14, 1995, March 26, 1996, July 22, 1996, and January 10, 1997.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date February 4, 1997

By Patricia J. Lee
Nuclear Materials Licensing Branch, Region III

R6

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02110
Status Code: 0
Fee Category: 7B 2B
Exp. Date: 200[illegible]30
Fee Comments: CODE 13
Decom Fin Assur Reqd: Y

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
Applicant/Licensee: FROEDTERT MEMORIAL LUTHERAN HOSP.
Received Date: 970113
Docket No: 3003444
Control No.: 302214
License No.: 48-04193-01
Action Type: Amendment

2. FEE ATTACHED
Amount: ~~X~~
Check No.: ~~X~~

* ADDL INFO
R6 - 399668

3. COMMENTS

Signed D. Hersey
Date 1-15-97

B. LICENSE FEE MANAGEMENT BRANCH (Check when Tellerscan 03 is entered /__/)

1. Fee Category and Amount: 7B 2B FEE NOT REQUIRED

2. Correct Fee Paid. Application may be processed for:
Amendment ✓
Renewal
License

3. OTHER

Signed SC
Date 1/22/97

JAN 2 8 1997

RECEIVED BY LFDCB
Date Jan. 22 1997
Log Jan 8 III
By SC
Date Completed 1/22/97

1997 JAN 22 PM 1:49

FROEDTERT
Memorial Lutheran Hospital

9200 West Wisconsin Avenue
P.O. Box 26099
Milwaukee WI 53226-3596
Telephone: 414 259 3000

January 10, 1997

U.S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
ATTN: Patricia Pelke
801 Warrenville Road
Lisle, Illinois 60532-4351

Re: License number 48-04193-01
Control Number 99668

Dear Ms Pelke:

This correspondence is in response to your request, dated November 19, 1996, regarding the compaction of waste generated from inpatient iodine-131 thyroid ablation radiotherapies. Attached is the information you requested.

If you require additional information or assistance, please contact me or Robert Yoss at (414)257-6540.

Sincerely,

Ralph Grunewald

Ralph Grunewald, Ph.D.
Radiation Safety Officer

cc: C. Runge

Cont'N 399668
FEE NOT REQUIRED

RECEIVED
JAN 13 1997
REGION III

Pmi 1-10-97

JAN 13
302214

1. A description of the type and model of the compactor used;
Two Sears Kenmore Household compactors. One is a model 665.8419000 and the other has no model number.

2. A description of the type(s), quantities and concentrations of waste to be compacted;
Disposable solid waste generated during the time the patient is hospitalized for compliance with 10 CFR 35.75. The waste consists primarily of solid waste generated by disposable dining utensils such as paper plates and cups.

3. An evaluation of the potential for airborne release of radioactive material during compaction activities;
An evaluation for the potential release of radioactive material for compaction concluded that release of radioactive material during compaction was not a significant potential source of airborne radiation. The potential for release of airborne release of radioactive material during compaction was evaluated based on published articles. References: Iodine-131 Contamination from Thyroid Cancer Patients, *Journal of Nuclear Medicine* 1992:33:2110-2115; How Harmful to Others Are Iodine-131 Treated Patients (Editorial), *Journal of Nuclear Medicine* 1992:33:2116-2117; Monitoring of I Excretions and Used Materials of Patients Treated With ^{131}I, *Health Physics* 1980:38:467-481; NUREG-1492, "Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material".

4. Specify the location (temporary and permanent) of the compactor;
The compactors are placed in the patient's room (temporary) during therapies and placed in the Radiation Safety Office radioactive waste holding room number 103 (permanent) when therapies are not in process. Room number 103 was formerly referred to as CC 196 when under the control of John L. Doyne Hospital.

5. Specify the types and frequencies of surveys that will be performed for contamination control;
Trash compactors are wiped tested prior to use for a therapy.

6. Submit a copy of the instructions that will be provided to compactor operators; and
See enclosed *TRASH COMPACTOR INSTRUCTIONS*.

7. Based on information obtained during the inspection, it appears that you transport the compactor between patient rooms. If this is the case, describe the permanent storage location for the compactor and describe the surveys that are performed prior to transport to assure no residual contamination is present.
The permanent storage location is a secured room used in part for the storage of radioactive waste. Entrance to the floor where the room is located is through an elevator with controlled access. The room is 22 x 16 feet. The ceiling height is 13.5 feet. The room has one entrance door. The room is constructed with a combination of poured concrete and cement blocks. There is a fume hood located in the room that is exhausted outside.

TRASH COMPACTOR INSTRUCTIONS

LOADING THE COMPACTOR

1. *Open drawer. The drawer can be opened by either pulling by hand or by foot using the "STEP-ON-IT" drawer opener. See figure 1.*

2. *Load trash.*
   - *A. DO NOT PLACE ANY CONTAINER WITH LIQUIDS IN THE COMPACTOR. Empty liquids into the sink or toilet.*
   - *B. DO NOT put styrofoam food trays in compactor. Place trays on top of compactor.*
   - *C. Food such as jello can be flushed down the toilet.*

3. *Compact trash. Make sure the "NORMAL/EXTRA PAC" button is on "NORMAL". See figure 2. Close drawer completely and turn "START" key knob momentarily to start. See figure 3. The key-knob will return to the on position automatically.*

Figure 1.



Figure 2.



Figure 3.



FEB 10 1997

Ralph Grunewald, Ph.D.
Radiation Safety Officer
Froedtert Memorial Lutheran Hospital
9200 W. Wisconsin Avenue
Milwaukee, WI 53226

Dear Dr. Grunewald:

Enclosed is Amendment No. 77 to your NRC Material License No. 48-04193-01 in accordance with your request. This amendment incorporates the compaction procedures you provided in response to our November 19, 1996 letter.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Sincerely,

Original Signed By
Patricia J. Pelke
Nuclear Materials Licensing Branch

License No.: 48-04193-01
Docket No.: 030-03444

Enclosure: Amendment No. 77

DOCUMENT NAME: M:\03003444.CL7
To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII							
NAME	PPELKE:jaw							
DATE	02/6/97							

OFFICIAL RECORD COPY

302214

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

January 16, 1997

Jerry Apple
Senior Vice President
Froedtert Memorial Lutheran Hospital
9200 W. Wisconsin Avenue
Milwaukee, WI 53226

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 01/10/97)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

___ New License _X_ Amendment ___ Renewal
___ Termination ___ Auth User (Amendment not required)
___ Other_____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.

2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.

3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 302214
License No. 48-04193-01